NASDAQ Biotechnology Index

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, February 29, 2024

On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.

Key Points: 
  • On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.
  • The DANYELZA net product revenues of $23.4 million in the fourth quarter of 2023, represented a favorable 17% increase compared to the third quarter of 2023, primarily driven by increased U.S. sales.
  • The Company did not have license revenues in the quarter ended December 31, 2023 and had license revenues of $0.5 million for the year ended December 31, 2023.
  • The net income for the quarter ended December 31, 2022, was after $15.0 million of license revenue recognized in the fourth quarter of 2022.

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024

"Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."

Key Points: 
  • "Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."
  • To arrange a meeting with management, please contact your Biotech Showcase representative or Lytham Partners at [email protected] .
  • The ceremony will feature healthcare companies within the Nasdaq Biotechnology Index, highlighting them as companies pioneering the future.
  • The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Retrieved on: 
Thursday, January 4, 2024

Beyond ZW191, we are planning additional IND filings and FIH studies for ZW220 (NaPi2b) and ZW251 (GPC3) to commence in 2025.

Key Points: 
  • Beyond ZW191, we are planning additional IND filings and FIH studies for ZW220 (NaPi2b) and ZW251 (GPC3) to commence in 2025.
  • “Our strong financial position allows us to be opportunistic in evaluating additional R&D opportunities and pursuing potential strategic partnerships and collaborations.
  • We expect to submit INDs for ZW171 and ZW191 in 2024, and INDs for ZW220 and ZW251 in 2025.
  • An R&D Day to highlight our progress and future R&D strategy will be held in the fourth quarter of 2024.

Zymeworks Added to Nasdaq Biotechnology Index

Retrieved on: 
Friday, December 15, 2023

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”).
  • Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023.
  • The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark.
  • The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.

Tourmaline Bio added to the NASDAQ Biotechnology Index

Retrieved on: 
Friday, December 15, 2023

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Tourmaline has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 18, 2023.

Key Points: 
  • NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Tourmaline has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 18, 2023.
  • The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark.
  • The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
  • Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria.

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

Retrieved on: 
Thursday, December 14, 2023

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.

Key Points: 
  • SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.
  • “2023 has been a transformational year for Ambrx, especially for our publicly held securities.
  • We believe these changes may help to enhance long-term shareholder value and further increase our profile in the investment community.”
    The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies and is a modified market capitalization weighted index.
  • To learn more about the NASDAQ Biotechnology Index, visit this link .

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

Retrieved on: 
Wednesday, December 13, 2023

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.

Key Points: 
  • NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023.
  • The NASDAQ Biotechnology Index is designed to track the performance of a set of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market (“NASDAQ”).
  • The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
  • Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria.

Savara Added to the NASDAQ Biotechnology Index

Retrieved on: 
Wednesday, December 20, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023.
  • The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
  • The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
  • Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria.

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change

Retrieved on: 
Thursday, November 16, 2023

Yet, Mr. Kellner and Mr. Deutsch are long-term stockholders who collectively own 6.5% of outstanding AIM stock – making them the largest stockholder or group of stockholders in the Company.

Key Points: 
  • Yet, Mr. Kellner and Mr. Deutsch are long-term stockholders who collectively own 6.5% of outstanding AIM stock – making them the largest stockholder or group of stockholders in the Company.
  • The facts show that AIM and Equels are misleading investors and they are clearly not protecting stockholders and the Company.
  • For AIM to have any chance of success, we believe that significant change in the Board is urgently needed.
  • THE KELLNER GROUP URGES ALL STOCKHOLDERS TO VOTE ON THE GOLD PROXY CARD TODAY TO ELECT TED D. KELLNER, TODD DEUTSCH AND ROBERT L. CHIOINI.